Block Drug
Executive Summary
President James Block becomes chairman. He fills a post vacated by his uncle Leonard Block, who assumes the newly created position of senior chairman of the family-controlled business. Exec VP Thomas Block, son of Leonard Block, is promoted to president. His former responsibilities are taken over by Donald LeSieur, who continues to head the company's U.S. marketing activities. Senior VP Michael Alfano and VP John Peters elected to board, expanding the number of directors to 12.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Nominates Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.